Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Biotechnology

Outlook Therapeutics

C. Russell Trenary III

Tony Moses

Surendra Sharma

Christoph Puetz

Lauren Nelson

Kathleen Billman

Jennifer Kissner

Entisar Dahan, MPM, PHR

Anu Wallecha

Terry Dagnon

Lawrence A. Kenyon

Jeff Evanson

The Leadership Team at Outlook Therapeutics is responsible for guiding the strategic direction of the company, overseeing the development and commercialization of ONS-5010 / LYTENAVA™. Comprising key executives such as the President & CEO, Chief Commercial Officer, CFO, and COO, this team collaborates to ensure operational excellence, drive financial growth, and navigate regulatory pathways to bring innovative treatments for retinal diseases to market.

Leadership Team

Directors

Operations Team

Leadership Team

About

Team members

Other teams at Outlook Therapeutics

Directors

Operations Team